The U.S. Food and Drug Administration yesterday approved aducanumab to treat Alzheimer’s disease, the most common cause of dementia. According to the Alzheimer’s Association, aducanumab is the first drug that slows Alzheimer’s disease, and its approval marks the beginning of a completely new future for Alzheimer’s treatments. “On behalf of those impacted by Alzheimer’s and all other dementia, the Alzheimer’s Association welcomes and celebrates today’s historic FDA approval of aducanumab for Alzheimer’s disease,” Harry Johns, the organization’s president and CEO, said in a press release. “This approval is a victory for people living with Alzheimer’s and their families. This approval allows people living with Alzheimer’s more time to live better. For families it means being able to hold on to their loved ones longer.” The association said it will do everything in its power to ensure access to the drug and FDA-required diagnostic testing for all who will benefit.